H epatic encephalopathy (HE) is a complex, neuropsychiatric abnormality that occurs as a consequence of metabolic disorders in patients with hepatic insufficiency. The pathogenesis is complex with a strong prognosticator of death. To standardize the clinical management of HE, relevant new data were reviewed and assessed by Chinese Committee of Experts on Hepatic Encephalopathy in China and was discussed and debated extensively. Then the consensus on the management of HE was developed. The final recommendations are based on the data available at the time of production of the document and may be updated with pertinent scientific developments at a later time. All the discussion was organized by the editorial board of Chinese Journal of Experimental and Clinical Infectious Diseases (Electronic Edition), Chinese Journal of Liver Diseases (Electronic Edition) and Infection International (Electronic Edition). The evidence gradings in the consensus are listed in Table  1 .
CONCEPT AND CLINICAL CLASSIFICATION OF HE

Definition
Hepatic encephalopathy is defined as a spectrum of neuropsychiatric abnormalities in patients with severe liver dysfunction (including acute or chronic liver failure) or portosystemic venous shunts after exclusion of other known brain diseases, which has potential reversibility. Its clinical features can be extensive and broad neuropsychiatric disorders, ranging from subtle deficits in central nervous system function (in mild cases) that can be detected only through intelligence or electrophysiological tests of personality changes, abnormal behavior, mental deterioration or even different levels of disturbance of consciousness or coma (in severe cases). The so-called hepatic coma is 
Clinical subtypes According to the classification proposed in the World
Congress of Gastroenterology 1998 in Vienna, hepatic encephalopathy is subdivided in type A, B and C.
1 Type A (acute) : HE associated with acute liver failure (fulminant hepatic failure, FHF) or subacute liver failure. After occurrence of HE, encephalopathic symptoms usually occured within two weeks in the former case and 2-12 weeks in the later case. Type B (bypass) : HE is caused by portal-systemic shunting without associated intrinsic liver disease, with normal liver histology. The clinical manifestation is the same as HE associated with liver cirrhosis. This portosystemic venous shunting can be spontaneous or caused by surgical or interventional operations, such as the porto systemic venous shunting caused by congenital vascular malformation, intrahepatic and extrahepatic portal vein obstructions (including the embolism or thrombosis of portal vein and its branches caused by trauma, carcinoid, myeloproliferative diseases and other diseases) and the portal hypertension resulting from lymphoma, metastatic tumor and cholangiocarcinoma oppression. Type C (cirrhosis): HE occurs in patients with cirrhosis. It is the most common type of HE, often with portal hypertension and/or porto systemic venous shunting. Liver failure is the main cause of encephalopathy, followed by porto systemic venous shunting. According to the severity of clinical symptoms, type-C HE is subdivided into minimal HE (MHE) or subclinical encephalopathy and symptomatic HE (SHE) ( Table 2 ). In China, most HE patients are type-C, which occured based on chronic liver disease and cirrhosis and often with portal hypertension and porto systemic venous shunting. HE of type A and type B are in relatively small number.
PATHOGENESIS
A number of theories have been proposed to explain the development of hepatic encephalopathy in patients DOI: 10.1515 DOI: 10. /ii-2017 with cirrhosis. But so far, the pathogenesis of HE has not yet been fully elucidated. Due to acute and chronic liver failure and/or porto-systemic venous shunting, the neurotoxic substances from intestinal veins will bypass the liver and directly enter the heart via another route without undergoing first-pass detoxification by the liver. Then the neurotoxic substances may gain entry into brain through the blood-brain barrier, and result in the dysfunction of the central nervous system. The hyperammonemia, a kind of neurotoxic substances, is recognized as one of the most critical factors, 2 especially in HE associated with chronic liver disease and cirrhosis (and/or with portosystemic venous shunting). All factors contributing to hyperammonemia include the increasing production of ammonia, the decreased mass of functioning hepatocytes, resulting in fewer opportunities for ammonia to be detoxified or portosystemic shunting diverting ammonia-containing blood away from the liver to systemic circulation. Ammonia has multiple neurotoxic effects, such as impairment of energy utilization in brain, impact of the balance between the central excitatory neurotransmitters (glutamate) and inhibitory neurotransmitters (such as glutamine, gama-aminobutyric acid, GABA), which resulted in central inhibition. Other hypothesis has also been postulated. For instance, false neurotransmitters (octopamine and phenylethanolamine) replacing the normal neurotransmitters which results in neurotransmission disorder. Reduced concentrations of branched-chain amino acids (leucine, isoleucine and valine) and increased concentrations of aromatic amino acids (phenylalanine, tyrosine and tryptophan) may promote hepatic encephalopathy by causing the production of false neurotransmitters. Benzodiazepines exert their depressant effects on the central nervous 
COMMON PRECIPITATING FACTORS
In HE cases with type-A, the basic liver injury was acute liver failure (fulminant hepatic failure, FHF) or subacute liver failure. A large number of liver cells were damaged and the gut-derived toxin could not be effectively removed, resulting in dysfunction of central nervous system. Type-A HE is a kind of endogenous HE, also known as non-ammonia encephalopathy, and often has no definite precipitating factors. Patients with simple type-B HE is rare in China. As for type-C HE, associated with chronic liver failure or porto systemic venous shunting, the detoxicating function of liver reduces. Once the production of toxicants increases and surpasses the compensatory liver detoxicating ability, then type-C HE occurs, which is largely related with the following precipitating factors.
Excessive intake of nitrogenous foods
Patients with chronic liver failure or porto systemic venous shunting have a poor tolerance with protein foods, especially animal protein. The overload of protein in intestinal tract will produce a large amount of ammonia and aromatic amino acid, which will cause HE. Oral ammonium salt, urea, methionine and other nitrogenous substances can increase the absorption of nitrogen substances, which will result in hyperammonia and cause HE.
Gastrointestinal bleeding
Massive blood (every 100 ml blood is equivalent to an intake of 15-20 g protein) in gastrointestinal tract results in increased ammonia and nitrogen absorption from the gut. Meanwhile, the leucine and valine increase in blood, which will stimulate the increase of activity of branched chain amino acid dehydrogenase and enhance branched chain amino acid decomposition, aggregating the ratio imbalance between branched chain amino acid and aromatic amino acid. Hemorrhagic hypovolemia, cerebral ischemia and hypoxia can also increase the sensitivity of central nervous system to ammonia and other toxin.
Infection
Spontaneous bacterial peritonitis, pneumonia, urinary tract infection and bacteremia can enhance tissue catabolism and increase blood ammonia levels, which can further cause endotoxemia, aggravate liver damage and increase the blood-brain barrier permeability and precipitate HE.
Electrolyte imbalance
Hyponatremia can affect intracellular and extracellular osmolality and cause brain edema, thus inducing HE; hypokalemia is often associated with metabolic alkalosis. Diuretic therapy and abdominal paracentesis to remove a large volume of fluid can also cause alkalosis, which may facilitate the conversion of NH 4 + to NH 3 . NH 3 is more easily absorbed from the intestine and passes through the blood-brain barrier and induces HE.
Azotemia
The hypovolemia caused by a variety of reasons, such as anorexia, diarrhea or liquid intake limitation, and large dosage of diuretics application or abdominal paracentesis can all induce pre-renal azotemia, hepatorenal syndrome or renal azotemia, which may also caused by other reasons. All these factors contribute to elevated blood ammonia levels.
Constipation
Constipation can prolong the exposurion of ammonia and other intestinal derived toxin to intestinal mucosal, which increases the absorption of these toxic substance.
Hypoglycemia
Hypoglycemia could decrease the capability of intracephalic detoxification for ammonia and other intestinal derived toxin. In the early days, the presentation of encephalopathy in most patients is recurrent and then become persistent, which often accompanied by the manifestations of chronic liver damage and cirrhosis. Usually, excessive dietary protein is a provocative factor, but type-C HE may occur spontaneously or after stopping HE treatment. A c c o r d i n g t o t h e d e g r e e o f c o n s c i o u s n e s s disturbance, nervous system manifestations and EEG changes of the patients and reference to Practical Internal Medicine, HE can be divided into five stages (0-4), but each stage may overlap or transfer from one stage to the next stage (Table 3) . 
Sedative
AUXILIARY EXAMINATION
Except for abnormal liver function, elevated serum bilirubin, separation of enzyme and bile (highly elevated serum bilirubin associated with liver enzymes reduced) and reduced prothrombin time activity, the examinations helpful to HE diagnosis are as following: blood ammonia
The fasting blood ammonia of normal people is 6-35μg/L (serum) or 47-65μg/L (whole blood). In patients with type-B and type-C HE, the blood ammonia rises, while in patients with type-A HE, the blood ammonia is often normal.
Plasma amino acids imbalance
Branched chain amino acids reduce and aromatic amino acids increase, resulting in the ratio of the two below 1 (> 3 in normal cases). But due to the requirment of special apparatus, no examination can be conducted at ordinary laboratory at present.
Neuropsychological and intelligence detection
It is significant to the diagnosis of MHE. At present, there are many methods for detection, but most of them are subject to age, gender and education level of the patients. Such methods are recommended as the Number Connection Test, part A (NCT-A, Appendix 4a-1) and part B (NCT-B, Appendix 4a-2); the LineTracing Test (LTT, Appendix 4b), the Brief Visuospatial 7) can well reflect the situation of slight neuropsychiatric damage which take too much time (a check takes 5 to 10 minutes). They all can be conducted in clinical trials.
Neurophysiological tests EEG
Generally, neurophysiological abnormality can be detected by EEG before biochemical or mental abnormalities. The main manifestation is slow rhythms, which usually appears on both sides of the forehead and the top and then gradually moves backward. EEG changes are not specific for HE, which can be detected in other metabolic encephalopathies such as uremic encephalopathy, but the severity of these changes is highly related to the clinical stage.
Evoked potentials (EPs)
There are many kinds of EPs, but endogenous event related EPs P300 with more sensitivity, is a better choice for the diagnosis of HE. However, due to the limitations of instrument, equipment and professionals, it is only applied in clinical trails.
Critical flicker frequency (CFF)
This method was originally applied for detection of the critical flicker frequency of warning disorders and can reflect the ability of central nervous system. In recent years, a compared study on 217 individuals (including cirrhosis patients and healthy population) in Spain showed that CFF can sensitively diagnose MHE (including minor HE and HE stage 1) and is reliable, simple, easy to apply. But as the application of CFF for diagnosis MHE is just on the start, further clinical application is required for its diagnostic value.
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Imaging examination Cranial CT and MRI can detect cerebral edema. Manganese deposition can cause changes in structure of astrocytes. In examination of head MRI, frontal cortex brain atrophy and enhanced T1-weighted signal of globus pallidus and core-shell capsule can be detected. The main value of cranial CT and MRI is to exclude other causes of an abnormal mental state including cerebrovascular accident, intracranial tumor and other brain diseases. HE is divided into different stages according to the severity of neuropsychiatric symptoms. Also, it can be graded according to West-Haven Scale, Glasgow Coma Scale or HESA.
DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS
Differential Diagnosis
Before diagnosis, HE should be discriminated with the following diseases: Psychosis HE, with psychiatric symptoms such as personality changes or abnormal behavior as the outstanding manifestations, can be easily misdiagnosed as psychosis. So, when the patients with serious liver diseases or porto systemic venous shunting history occurs neurological and psychiatric disorders, HE should be considered. Other metabolic encephalopathies Ketoacidosis These patients with a history of diabetes get ill usually caused by infection, emergency or overeating, alcoholism, etc. The manifestations include aggravated diabetes, loss of appetite, nausea, vomiting, abdominal pain, dizziness, headache, blurred consciousness and lethargy. The blood sugar is often greater than 16.7 mmol/L (300 mg/dl) with positive urine acetone bodies. Hypoglycemia Hypoglycemia may cause coma, often accompanied by sympathetic excitement, dizziness, palpitation, cold sweats, etc. Blood glucose concentration is often less than 2.8 mmol/L, and the symptoms may disappear after sugar supplement.
Renal encephalopathy
The manifestations also include mental retardation, delirium, hallucination, asterixis, lethargy and even coma, but these patients have a history of acute/ chronic kidney disease and the evidence of azotemia, with reducing endogenous creatinine clearance rate, increasing blood urea nitrogen and creatinine or organic damage of kidney.
Pulmonary encephalopathy
The symptoms include headache, dizziness, memory loss, lack of energy and reduced ability. The more serious symptoms include drowsiness, lethargy, coma, positive asterixis and ankle clonus. However, the patients have a history of respiratory diseases, associated with hypoxia and carbon dioxide retention manifestation. The PaO 2 reduces and PaCO 2 increase in blood, carbon dioxide combining power rises and blood pH decreases.
Neurological diseases Intracranial hemorrhage and intracranial tumor
These patients generally have nervous systemic positioning signs. The patients with intracranial hemorrhage may have a history of high blood pressure. Cranial CT or MRI can detect the focus.
Intracranial infection
The symptoms include fever and infection poisoning. It has meningeal irritation signs. Cerebrospinal fluid examination can be helpful to diagnosis. Reye syndrome This is a group of syndromes featuring the cerebral edema and liver dysfunction caused by fat visceral organ infiltration. Its prominent clinical manifestations include liver dysfunction and cerebral edema. High blood ammonia, low blood sugar, prolonged prothrombin time, elevated serum transaminases and low serum bilirubin often occur too. So, it is easily misdiagnosed as acute HE. But Reye syndrome often occurs on children catching upper respiratory tract infection and taking salicylates (aspirin). A large amount of fat droplets in liver cells are helpful to diagnosis.
Toxic encephalopathy
Drugs and toxins such as carbon monoxide, alcohol, heavy metals like mercury and manganese can cause toxic encephalopathy. A thorough understanding of medical history will be helpful to its identification. Alcoholic liver disease can also result in HE, so it needs to be distinguished with the encephalopathy caused by ebrietas from HE. Diagnosis process of HE (Figure 1) 
TREATMENT PRINCIPLES AND MEASURES
HE is a complex metabolic disorder caused by a combination of factors, so comprehensive measures should be taken in many aspects. Different treatment schemes should be designed according to clinical types, different provocative factors and the severity of disease. Early recognition and prompt appropriate treatment is the key to improve HE prognosis, so aggressive treatment is necessary when determining the with sleep disorder should not take benzodiazepine to avoid inducing clinical HE (C).
Symptomatic and supportive treatment
Patients with HE often lose appetite or in a coma and could not eat. So the active nutritional support is necessary.
Enteral nutrition
In the past, it was recognized that restricting protein diets may reduce intestinal ammonia production and prevent exacerbations of HE. However, recent research found that patients with cirrhosis often suffer from malnutrition. Although strict protein restriction can prevent elevated blood ammonia, it can further deteriorate the nutritional status of the patients and increase the risk of liver damage and death. Positive nitrogen balance is favorable for liver cell regeneration and the ammonia detoxification of muscle tissue. Recently, Cordoba et al conducted a clinical control study which randomized 30 patients with episodic HE to either low-protein diet group (protein intake rose from 0 g/d to 12 g/d on the third day and the figure doubled each three days till hitting 1.2 g/kg per day on the last two days) or normal protein diet group (1.2 g/kg per day). 8 The results showed that there was no obvious difference in mental function improvement and the rate of protein synthesis between the two groups, but the protein catabolic rate of patients in the low-protein diet group is obviously higher during the 14-day observation period. ESPEN (European Society for Clinical Nutrition and Metabolism) Guidelines on Enteral Nutrition amended in 2006 suggests a patient with liver disease is supplied with 146-167 kJ/kg existence of MHE.
Identification and removal of provocative factors
Type-C HE has a variety of provocative factors. Actively searching and immediate elimination may effectively inhibit the development of HE. For instance, esophageal variceal bleeding can induce the onset of HE. Active hemostasis, anemia correction and intestinal blood clearing are favorable for HE control; active infection control, correction of electrolyte disturbance, elimination of constipation and improvement of renal function are also the basic therapies to control HE.
Treatment of MHE
MHE patients mostly have no obvious symptoms and signs. But the patients may have weaker operating ability and sleep disorders. Treatment options: a. To adjust the diet structure and appropriately reduce protein intake (referring to enteral nutrition); b. Try nonabsorbable disaccharides such as lactulose or lactitol (referring to reducing intestinal pH and inhibiting the growth of intestinal bacteria); c. Patients (35-40 kcal/kg) of non-protein calories and a protein intake of 1.2-1.5 g/kg per day. 9 
Recommendations
In patients with HE type-A or HE type-C in stage 3 or stage 4, protein feeding can be withdrawn for the few beginning days (C). After getting sober, the protein intake increases 10 g every 2-3 days gradually, aiming at 1.2 g protein·kg -1 ·day -1 (range 1-1.5 g) (A); As for Water, electrolyte and acid-base balance Hyponatremia, hypokalemia, hyperkalemia and alkalosis are all important precipitating factors to HE, and active corrections should be given according to the level of serum electrolytes and blood gas analysis results. The fluid volume of daily supplementation should be determined according to the urine volume of previous day (urine volume + 1000 ml) and the total volume should be controlled within 2,500 ml.
Treatment of basic diseases
Patients with hypoproteinemia may maintain colloid osmotic pressure by intravenous infusion of plasma and albumin. Albumin supplementation can also promote the repair of liver cells. As for patients with brain edema, alternate rapid infusion of 20% mannitol or 50% glucose should be adopted; moreover, adequate vitamin B, vitamin C, vitamin K, ATP and co-enzyme A should be added to improve the energy metabolism of brain.
Treatment targetting at the pathogenesis
Reduction in the production and absorption of ammonia and other harmful substances from the intestinal tract Bowel cleansing Because the toxins responsible for HE chiefly arise from the gut, bowel cleansing is a mainstay of therapy. Colonic cleansing can reduces the luminal production and absorption of ammonia and other toxic substances, and could lower blood ammonia in cirrhotic patients. The retention of food, blood or other toxic substances in intestinal tract can be cleaned through catharsis or enema. Recommendations Twenty five percent magnesium sulfate (30-60 ml, ingested or via nasogastric tube p.o.) could be given for catharsis. Irrigation with non-absorbable disaccharides solution (such as lactulose, 300-500 ml in 500 ml water) can also be taken for enema, especially suitable for HE with porto systemic venous shunting.
Reducing intestinal pH and inhibiting the growth of intestinal bacteria
Application of non-absorbable disaccharides (lactulose and lactitol) 12 Lactulose is a kind of disaccharide. As there is no lactulose enzyme in the human digestive tract, it is not broken down by intestinal disaccharidases and not absorbed in the stomach and small intestine. Thus, it could reach the colon, where bacteria will metabolize the disaccharidases to acetic acid and lactic acid. This could lower the colonic pH, inhibit intestinal ammonia production, and promote the conversion of lumenal ammonia (NH 3 ) to ammonium (NH 4 + ), which should be less readily absorbed into the bloodstream from the bowel lumen. The production of organic acids by bacterial fermentation can also increase bowel lumen osmotic pressure, with the acidification of the colon, underlies its cathartic effect, which is helpful for the discharge of ammonia and other toxic substances in intestinal tract. Non-absorbable disaccharides, as prebiotics, are hostile to the survival of ureaseproducing intestinal bacteria and reduce the production of ammonia in colon. Abdominal discomfort, flatulence, and abdominal cramping, anorexia, nausea, vomiting and diarrhea are the most frequent subjective complaints with this drug. The miscellaneous sugar content of non-absorbable disaccharides is low (2%), so it is also applicable to patients with diabetic or lactase deficiency. However, they should be forbidden in patients with ileus. A number of randomized control studies showed that lactulose or lactitol can remarkably improve HE and the life quality of patients than placebo, but it still remains unknown whether it can improve the patients survival rate.
12,13
Recommendations For patients with acute encephalopathy, lactulose (ingested or via nasogastric tube, 45 ml p.o. ) is given every hour until evacuation occurs.
2 Then the dose is adjusted to an objective of two to three soft bowel movements per day (generally 15-45 ml every 8-12 hours) (A); Lactulose by enema (300 ml in 1 L water) is retained for 1 hour, with the patient in trendelenburg position (to increase the possibility of access to the right colon). For patients with chronic encephalopathy, oral lactulose does not require the hourly initial administration. Lactitol, the lactulose derivative, has the same mechanism of action and effect as lactulose. But it is more palatable and better tolerated. The usual dose is 0.5 g/kg, bid, which can be adjusted to an objective of two to three soft bowel movements per day (A).
Application of probiotics
The probiotics (including bifidobacterium and lactobacillus) can restrict the growth of ammoniaproducing and urease-producing intestinal bacteria by adjusting the structure of intestinal flora, resulting in reduced production and absorption of intestinal ammonia and other toxic substances. It can be applied together with prebiotics. In a recent open study, 190 patients with cirrhosis (55% with MHE) were randomly divided into 3 groups to respectively receive lactulose 30-60 ml/d or probiotic capsule (a quadrigeminus active bacterial agent including lactobacillus and streptococcus faecalis, etc.) or receive both kinds of treatment. After 1 month treatment, the patients achieved obvious improvement on neuropsychological test, P300 auditory evoked potential and the ammonia level in blood, but there was no significant difference among the efficacy of three groups.
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Recommendations
Live combined bifidobacterium, lactobacillus and enterococcus capsules, 2-3 tablets/time, tid, p.o.; Bacillus licheniformis capsules, 2 tablets /time, tid (B).
Application of antibiotics
Antibiotic is a therapeutic alternative to nonabsorbable disaccharides for treatment in acute and chronic HE.
In the past, it is recognized that oral intake of few-absorbable aminoglycoside antibiotics such as neomycin is beneficial to inhibit the overgrowth of colonic bacteria. However, the recent randomized placebo control study showed that neomycin is essentially contraindicated; it was found that a proportion of the ingested dose is indeed absorbed due to increased gut permeability, thus the risk of ototoxicity and renal toxicity and small intestine mucosa dysfunction may occur. Metronidazole can inhibit intestinal anaerobic bacteria and improve HE, but long-term use may result in the alteration of intestinal flora, gastrointestinal discomfort or neurotoxicity.
15 Non-aminoglycoside antibiotics rifaximin is a derivative of rifampin and has a broadspectrum and strong restriction on the growth of bacteria in intestinal tract. It is non-absorbable and only locally works in the gastrointestinal tract. It showed that 550 mg rifaximin in succession (bid), can remarkably prevent the occurrence of HE than placebo. 16, 17 In terms of chronic HE treatment, rifaximin has an effect equal to that of lactulose or neomycin and has no toxicity to the auditory nerve and renal function.
17,18
Recommendations Rifaximin 1,200 mg/d, tid (A).
The combination of antibiotics and non-absorbable disaccharides
Retrospective data analysis showed that the combination of two drugs can significantly lower the patients hospitalization rate and hospitalization time, but its potential therapeutic benefit remains to be further studied.
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Promote the metabolism of ammonia, antagonize false neurotransmitter and improve the balance of amino acids Ammonia-lowering drugs a. L-ornithine-L-aspartate (L-ornithine L-aspartate, LOLA,OA): OA is a stable salt of the 2 constituent amino acids. L-ornithine is the substrate of urea cycle (ornithine cycle). It can increase the activity of carbamoyl phosphate synthetase and ornithine carbamyl transferase and stimulates the synthesis of urea resulting in loss of blood ammonia. Both L-ornithine and L-aspartate are substrates for glutamate transaminase. With the administration of aspartate, ammonia is applied in the conversion of glutamate to glutamine and detoxification. Therefore, administration of OA can reduce the blood ammonia level. Aspartate is also involved in the synthesis of nucleic acids in the liver cells and indirectly promotes the metabolic process of Krebs cycle within the liver cells, thus facilitating the repair of stem cell. Clinical studies showed that compared with placebo control group, 20 g/d OA intravenous infusion can significantly reduce fasting blood ammonia and postprandial blood ammonia and improvement in the mental state grade of HE patients. 20 Oral administration of OA can improve the results of NCT-A, asterixis and EEG in patients with HE.
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Recommendations For acute and chronic HE patients, OA (40 g) can be given within 24 hours. After patients getting sober, the dose of OA can be reduced to 20 g/d. For vein tolerability, the OA dose per 500 ml of solution should not exceed 30 g. The injection speed should not exceed 5 g/h. Thus such adverse reactions as nausea and vomiting could be avoided (A). b. Arginine: As an intermediate metabolite ornithine cycle in the process of urea synthesis in liver, it can promote the synthesis of urea and lower blood ammonia. The clinical preparations are its hydrochloride salt. Being acidic, it can acidify blood and reduce the toxic effect of ammonia on the center. Recommendations Arginine hydrochloride (25%, 40-80 ml added to the glucose solution, i.v. q.d.) can be used (A). It can also correct alkalemia. c. Glutamate: As the substrate of glutamine synthesis, sodium glutamate and potassium glutamate can reduce blood ammonia and adjust the balance between potassium and sodium. However, it is believed in recent years that glutamate can only temporarily reduce ammonia, and could not penetrate blood-brain barrier and reduce the ammonia in brain tissue, and may induce metabolic alkalosis and aggravate HE. In addition, the hypertonic effect caused by the excessive glutamine in brain is involved in the formation of brain edema, which is unfavorable to the recovery of HE. Therefore, it is no longer recommended for HE treatment. The effect of antagonistic false neurotransmitters Endogenous benzodiazepine analogues binding to the γ-aminobutyric acid receptor complex has been proposed as an important factor in the pathogenesis of HE. Theoretically, it is feasible to use fumazenil, the antagonist of the receptor for HE treatment. A large clinical trial of 560 cases showed that the improvement rate of brain function in patients treated with fumazenil or placebo is 15% and 3%, respectively.
2 The other 12 controlled studies on 765 patients showed that fumazenil can significantly improve HE, but did not show long-term benefits or improve the survival rate of patients. Therefore, its application is only considered for the patients who recently received benzodiazepines. Alterations of dopaminergic neurotransmission were initially postulated to contribute to the pathogens of HE. However, clinical controlled trials showed that the application of bromocriptine and levodopa could not give other benefits to HE patients in addition to partially improving the extrapyramidal symptoms of HE patients. 
Correction of the imbalance between aromatic and branched-chain amino acids
Oral administration or intravenous infusion of branched-chain amino acid can correct amino acid metabolic imbalance and inhibit the formation of false neurotransmitters in brain. A meta analysis on five trials showed that the intravenous infusion of branched-chain amino acids can significantly improve the symptoms of HE. Although two of the five trials and another trial failed to reduce the mortality of HE patients by branched-chain amino acids, 3 two large-scale trials in recent years (randomized control trials on 174 and 622 patients with cirrhosis, respectively) showed that the application of branched-chain amino acids not only reduce the incidence of HE, but also improve the nutritional status of patients, improve liver function, decrease the incidence of liver failure and improve the survival rate of HE. Other trials showed that branchedchain amino acids can also stimulate liver cells regeneration. Adequate intake of branched chain amino acid mixture is effective to restore the patients' positive nitrogen balance, increase patients tolerance to protein food and improve their cerebral blood perfusion.
11 Its main side-effects include nausea, vomiting and allergic reactions, so the speed of infusion should be slow. Recommendations Branched chain amino acid mixture (250-500 ml q.d. i.v.) can be recommended (A).
Treatment of underlying diseases
Type A HE or type C HE occurs in patients with acute and chronic liver failure, respectively. Therefore, aggressive treatment of hepatic failure (referring to the Diagnostic and Treatment Guidelines for Liver Failure) is the fundamental prevention method to HE.
Liver function improvement
For chronic liver failure caused by viral hepatitis B, antiviral treatment with nucleoside or nucleotide analogues is indicated, which is helpful to mitigate or eliminate liver inflammation, necrosis and promote regeneration, helpful to restore liver's metabolism and detoxification function. For acute liver failure, due to the rapid progress of the disease, it may be hard to work on antiviral therapy, and the patients need to be transferred to ICU for comprehensive treatment.
Artificial liver support system
The system can be divided into non-biological type, biological type and mixed type. But only non-biological type is widely used in current clinical treatment, including hemodialysis, hemofiltration, plasmapheresis, hemoperfusion and plasma adsorption. Artificial liver support system can replace some functions of the liver to clear the accumulation of poisons in the body and provide conditions and times for the regeneration of liver cells. It is a transition therapy for patients waiting for liver transplantation and can be used in acute or chronic HE. But, in case of acute liver failure or endstage liver disease, liver transplantation may be the only useful therapy.
Liver transplantation
For some severe HE, internal medicine therapy could not work well, then orthotopic liver transplantation may be the only effective treatment method. Blocking porto systemic venous shunting Theoretically, a permanency or temporary blocking of serious porto systemic venous shunting in patients with HE may be helpful to improving patients mental state. However, due to the existence of portal hypertension, the method could increase the risk of gastrointestinal bleeding, so it should be weighed thoroughly before
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